What is the rating for PROK stock?

PROKIDNEY CORP. (PROK) has a "Avoid" rating based on our 6-factor quantitative model. It has a composite score of 35.5 and ranks #4060 out of 7,333 stocks in our coverage universe with a 1-star rating.

Is PROK a good stock to buy?

Based on our quantitative analysis, PROK receives a "Avoid" rating with 1 out of 5 stars. Key factors include: Quality score of 32.2, Value score of 30.2, and Momentum score of 48.5. The timing score is 49, indicating "Neutral" entry conditions. This is not investment advice - please conduct your own research.

What sector is PROK in?

PROKIDNEY CORP. (PROK) operates in the Manufacturing sector, specifically in the Pharmaceutical Products industry. It has a market capitalization of $0.71 billion.

What is PROK's P/E ratio?

P/E ratio data is not currently available for PROK.

Does PROK pay a dividend?

PROK does not currently pay a dividend.

What is PROK's market cap?

PROKIDNEY CORP. (PROK) has a market capitalization of $0.71 billion, making it a small-cap stock.

What are the risks of investing in PROK?

Key risk factors for PROK include: higher volatility, notable short interest, and general market risk. As with all investments, there is risk of loss.

How does PROK compare to peers?

Within the Manufacturing sector, PROK ranks #4060 overall with a quality score of 32.2/100 and value score of 30.2/100.

What is PROK's revenue growth?

Revenue growth data is not currently available for PROK.

What is PROK's composite score?

PROKIDNEY CORP. (PROK) has a composite score of 35.5/100, which places it at rank #4060 out of 7,333 stocks. This score is derived from our proprietary 6-factor quantitative model that evaluates quality, value, momentum, investment efficiency, stability, and short interest.

How does PROK compare to the S&P 500?

PROK ranks in the top 45% of all stocks in our coverage universe with a composite score of 35.5. This places it below the market median.

What are the bull and bear cases for PROK?

Bull case: PROK scores highest in momentum at 48.5/100, indicating strong performance in this area. Bear case: The weakest factor is stability at 18.5/100, which may present a risk. Our overall assessment is Avoid with 1 out of 5 stars.

Is PROK overvalued or undervalued?

PROK appears overvalued based on our value factor score of 30.2/100.

What is PROK's momentum score?

PROK has a momentum score of 48.5/100, placing it in the moderate category.

When is PROK's next earnings date?

For the latest earnings date and analysis for PROK, visit our earnings calendar or check the PROK stock page for real-time updates. Our AI-generated earnings reports provide in-depth analysis after each quarterly report.

Is PROK a good stock to buy right now?

Based on our 6-factor quantitative model, PROKIDNEY CORP. (PROK) receives a "Avoid" rating with a composite score of 35.5/100. It is ranked #4060 out of 7,333 stocks. Key factor scores: Quality 32/100, Value 30/100, Momentum 49/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for PROK?

PROKIDNEY CORP. (PROK) has a "Avoid" rating and 1-star score. The composite score of 35.5 ranks it #4060 among 7,333 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is PROK in?

PROKIDNEY CORP. operates in the Manufacturing sector (Pharmaceutical Products industry) with a market cap of $712 million. It is classified as a small-cap stock.

Does PROK pay a dividend?

PROK does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is PROK's P/E ratio?

P/E ratio data is not currently available for PROK, which may indicate the company is not yet profitable.

How profitable is PROK?

PROK's quality factor score is 32/100. Gross margin: 100.0%. ROE: -26.6% vs sector average -1.9%. High margins suggest pricing power and competitive moats.

How is PROK valued compared to peers?

PROK's value factor score is 30/100 (higher = cheaper). Key multiples: . Trading at a premium relative to peers.

What is PROK's debt level?

Debt data is not available for PROK.

PROK has a beta of 2.08, meaning it amplifies market moves. Stability score: 19/100.

Does PROK have high short interest?

PROK's short interest factor score is 20/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

PROK Stock Analysis — PROKIDNEY CORP. Price Target & Forecast 2026

IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.

HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.

RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.

PROK Stock Analysis — PROKIDNEY CORP. Price Target & Forecast 2026 | Blank Capital Research

Sector

Manufacturing

Industry

Pharmaceutical Products

Market Cap

$712M

Leadership

Timothy A. Bertram

Business Summary

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Operations

Headcount

Location

HQ Base

Pending Verification

Fundamental Spot Check

Context: 2025

Valuation

Market Cap

$712M

P/E Ratio

P/B Ratio

P/S Ratio

442.86xLagging

EV/EBITDA

Dividend Yield

0.00%

Efficiency & Risk

Gross Margin

100.0%Outperforming

Operating Margin

-17907.5%Lagging

ROE

-26.6%Lagging

Rev Growth (YoY)

Debt/Equity

Beta

2.08

Red = Sector Laggard

Black = Market Average

Revenue Breakdown

Strategic Timing Audit

WEAK

0/6

Negative Alignment — Extreme Caution

Quantitative Factor Convergence Analysis Verified

Momentum

49th pctl

Intelligence Feed

insidermonkey.comDec 27 Positive

ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright

ProKidney Corp. (NASDAQ:PROK) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, ProKidney Corp.

BenzingaApr 15 Negative

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms. Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Soligenix, Inc. (NASDAQ: SNGX) shares surged 71.5% to $0.6679 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA. Longeveron Inc. (NASDAQ: LGVN) surged 54% to $2.6350 following insider buys from multiple company executives. SuperCom Ltd. (NASDAQ: SPCB) shares gained 39.4% to $0.3849 after jumping around 18% on Friday. Piedmont Lithium Inc. (NYSE: PLL) shares gained 32.1% to $16.75 following a 5% decline on Friday. Snap One Holdings Corp. (NASDAQ: SNPO) surged 31.6% to $10.71 after the company announced that it will be acquired by Resideo Technologies. Organovo Holdings, Inc. (NASDAQ: ONVO) shares surged 30.9% to $1.32 after the company announced Phase 2 results for FXR314. Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo. Kuke Music Holding Limited (NASDAQ: KUKE) jumped 27% to $2.7650. HUB Cyber Security Ltd. (NASDAQ: HUBC) gained 24% to $1.61 after gaining over 11% on Friday. Edgio, Inc. (NASDAQ: EGIO) gained 24% to $22.18. Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) ...

Zacks Investment ResearchJun 21 Neutral

Play Likely Earnings Beat With 3 Top-Ranked Stocks

Top-ranked stocks Wingstop (WING), Burlington Stores (BURL) and Prokidney CP (PROK) are likely to beat on the bottom line in their upcoming releases.

Zacks Investment ResearchDec 13 Positive

Here's Why ProKidney Corp. (PROK) Is a Great 'Buy the Bottom' Stock Now

ProKidney Corp. (PROK) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

benzinga.comJan 2 Negative

12 Health Care Stocks Moving In Friday's After-Market Session

Earnings Call Transcripts

Unlock Valuation Tools

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Financial Intelligence Ledger

Verified SEC Filings Aggregate • PROK

Export

Metric Entity	10Y Historical Trend	2024	2023	2022	2021
Revenue		$76K	$0	$0	$0
Cost of Revenue	-	—	—	—	—
Gross Profit	-	—	—	—	$0
R&D Expense		$128M19.6%	$107M30.0%	$82M77.4%	$46M
Operating Expenses	-	—	—	—	—
Operating Income		-$184M21.2%	-$152M1.0%	-$153M177.6%	-$55M
Interest Expense		$9K25.0%	$12K94.4%	$215K	$0
Tax Provision		-$598K110.0%	$6M569.2%	$896K	$38K
EBITDA		-$184M21.2%	-$152M1.0%	-$153M188.0%	-$53M
Net Income		-$163M20.6%	-$135M8.6%	-$148M168.6%	-$55M
EPS (Diluted)		-	-	$-0.23	$0.00

SEC EDGAR Repository

Direct unfiltered access to 10-K, 10-Q and 8-K filings for PROK.

Open Regulatory Dossier

Data Integrity Notice

Figures adjusted for stock splits and restatements where applicable.

TTM (Trailing Twelve Months) data updates within 48 hours of quarterly filings.

Execution Benchmarks Audit

Gross Margin

Core pricing power

+127% SCTR

100.0%

Sector Avg: 44.1%

Operating Margin

Operating efficiency

-713547% SCTR

-17907.5%

Sector Avg: 2.5%

Return on Equity

Equity efficiency

+1301% SCTR

-26.6%

Sector Avg: -1.9%

Dividend Yield

Direct cash return

-NaN% SCTR

0.0%

Sector Avg: 0.0%

Financial History

Forensic Accounting Audit

Watchlist

Margin Integritymedium RISK

High margin volatility — erratic forensic earnings quality

Algorithmic red flag detection based on regulatory SEC filings.

Unlock Financial Statements

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Shareholder Returns

Capital Allocation audit

Smart Money Conviction

Neutral

Synthesized from recent 13F filings, Form 4 insider transactions, and outstanding short interest metrics.

Governance Audit

Weak Index

WeakModerateStrong

Lower quality and stability scores may indicate governance concerns. Verified against factor-based integrity benchmarks.

Executive Operations

CEO: Timothy A. Bertram

Insider alignment Audit

No recent insider transactions available for PROK

Major Institutional Blocks

Top 5 Holders

Institutional cap table data requires verified 13F filing feeds.

Access SEC 13F Dossier →

Form 4 Filings

Recent Activity

Insider transaction data currently awaiting regulatory verification.

Access SEC Form 4 Dossier →

Regulatory Disclosure Vault

Proxy Statement (DEF 14A)

Exec Comp, Board Nominees, Proposals

Annual Report (10-K)

MD&A, Risk Factors, Strategy

Institutional Holders (13F)

Loading institutional data...

Insider Liquidity

Short Interest audit

SEC Risk Factors

Unlock Governance & Ownership

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Unlock Factor Analysis

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Unlock Investment Thesis

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Institutional Peer Matrix

Top Manufacturing Universe

Stock	Rating	Score▼	Quality	Value	Momentum	P/E	EV/EBITDA	ROE	ROA	Gross Mgn	Op Mgn	Net Mgn	Rev Growth	Div Yield	D/E	Mkt Cap	AUDIT
$UL UNILEVER PLC		78	96	98	59	-	-	-	-	-	-	-	-	-	-	$0	VS
$ASML ASML HOLDING NV		77	89	86	83	-	-	-	-	-	-	-	-	-	-	$0	VS
$ESLT ELBIT SYSTEMS LTD		76	81	87	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$MT ArcelorMittal		75	71	98	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$AMAT APPLIED MATERIALS INC /DE		75	85	87	84	20.9x	13.6x	32.9%	20.5%	48.8%	30.6%	24.4%	7.7%	0.9%	32.0x	$148.6B	VS
$SIMO Silicon Motion Technology CORP		75	84	86	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$CODA Coda Octopus Group, Inc.		74	83	90	79	16.3x	11.9x	7.4%	7.5%	68.3%	19.5%	18.2%	29.0%	0.0%	0.0x	$84M	VS
$GSK GSK plc		74	84	90	70	-	-	-	-	-	-	-	-	-	-	$0	VS
$EFXT Enerflex Ltd.		74	80	91	83	-	-	-	-	-	-	-	-	-	-	$0	VS
$BUD Anheuser-Busch InBev SA/NV		74	84	97	63	-	-	-	-	-	-	-	-	-	-	$0	VS
$PROK PROKIDNEY CORP.		36	32	30	49	-	-	-26.6%	-43.2%	100.0%	-17907.5%	-16581.5%	-	0.0%	-	$712M
SECTOR BENCH	-	-	-	-	-	22.3x	11.5x	-1.9%	0.9%	44.1%	2.5%	1.0%	6.7%	0.0%	0.2x	-	REF

Access Full Manufacturing Intelligence Archive →

Lateral Comparison Mesh

$PROK / $UL AUDIT $PROK / $ASML AUDIT $PROK / $ESLT AUDIT $PROK / $MT AUDIT $PROK / $AMAT AUDIT

Market Intelligence FAQ

PROKIDNEY CORP. (PROK) receives a "Avoid" rating with a composite score of 35.5/100. It ranks #4060 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.

Full Research Publication

Equity Research Analysis: PROKIDNEY CORP. (PROK)

FEBRUARY 2026|Blank Capital Research Unit|Spot: $2.22

Price$2.22

Composite Score35.5/100

RatingAVOID (1★)

Rank#4060 OF 7,333

Market Cap$712M

ROE

Comments

Institutional Audit

Feb 25, 2026

PROKIDNEY CORP.

35.5

Sector Decomposition auditManufacturing [N=1000]

Factor	Global	Sector	Tilt
PROFITABILITY	32	20	+12ALPHA
MOMENTUM	49	43	+6ALPHA
VALUATION	30	20	+10ALPHA
INVESTMENT	42	79	-37DRAG
STABILITY	19	6	+13ALPHA
SHORT INT	20	5	+15ALPHA

Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.

Executive Summary

Our quantitative model flags PROKIDNEY CORP. with an Avoid rating, assigning a composite score of 35.5/100 and 1 out of 5 stars. Ranked #4060 of 7,333 stocks, PROK falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.

Business Quality

PROK's quality score of 32/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -26.6% (sector avg: -1.9%), gross margins of 100.0% (sector avg: 44.1%), net margins of -16581.5% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.

Intrinsic Valuation

With a value score of 30/100, PROK appears somewhat expensive relative to its fundamentals. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.

Capital Reinvestment

With an investment score of 42/100, PROK exhibits moderate growth-oriented spending. Key growth metrics include a return on assets of -43.2% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.

Market Momentum

PROK is currently showing below-average momentum at 49/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth data is not currently available, while a beta of 2.08 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.

Balance Sheet Health

PROKIDNEY CORP. registers a low stability score of 19/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 2.08. Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.

Institutional Risk Profile

PROKIDNEY CORP.'s short interest score of 20/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 2.08), small-cap liquidity risk. At $712M (small-cap), PROK carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.

Sector Benchmark Analysis

PROKIDNEY CORP. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4060 of 7,333 overall (45th percentile). Key comparisons include ROE of -26.6% trailing the -1.9% sector median and operating margins of -17907.5% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.

Comparative Research Mesh

PROK VS S&P 500 (SPY)TOP MANUFACTURING PEERS

Strategic Alternatives

While PROK currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.

View Top Manufacturing Alpha →

PROK

PROKIDNEY CORP.

Business Summary

Operations

Location

Fundamental Spot Check

Valuation

Efficiency & Risk

Intelligence Feed

ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Play Likely Earnings Beat With 3 Top-Ranked Stocks

Here's Why ProKidney Corp. (PROK) Is a Great 'Buy the Bottom' Stock Now

12 Health Care Stocks Moving In Friday's After-Market Session

Unlock Valuation Tools

Unlock Financial Statements

Unlock Governance & Ownership

Unlock Factor Analysis

Unlock Investment Thesis

Lateral Comparison Mesh

Comments

Unlock Performance & Technicals

Economic Moat Audit

Economic Value Creation

Margin Superiority

Reinvestment Efficiency

Growth Durability

Financial Resilience

Uncertainty Audit

01Executive Summary

02Strategy & Outlook

Risk / Reward Variance

Research Verdict

Related Stocks

Executive Summary

Business Quality

Intrinsic Valuation

Capital Reinvestment

Market Momentum

Balance Sheet Health

Institutional Risk Profile

Sector Benchmark Analysis

Comparative Research Mesh

Strategic Alternatives

Factor Dispersion Audit

Sector Variance Findings

Market Intel

Intelligence Feed

ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Play Likely Earnings Beat With 3 Top-Ranked Stocks

Here's Why ProKidney Corp. (PROK) Is a Great 'Buy the Bottom' Stock Now

12 Health Care Stocks Moving In Friday's After-Market Session